Extended duration of the detectable stage by adding HPV test in cervical cancer screening.
The human papillomavirus test (HPV) test could improve the (cost-) effectiveness of cervical screening by selecting women with a very low risk for cervical cancer during a long period. An analysis of a longitudinal study suggests that women with a negative Pap smear and a negative HPV test have a strongly reduced risk of developing cervical abnormalities in the years following the test, and that HPV testing lengthens the detectable stage by 2-5 years, compared to Pap smear detection alone.
van den Akker-van Marie
M E
ME
Department of Public Health, Erasmus MC, PO Box 1738, 3000 DR Rotterdam, The Netherlands. vandenakkervanmarie@pg.tno.nl
van Ballegooijen
M
M
Rozendaal
L
L
Meijer
C J L M
CJ
Habbema
J D F
JD
D000328:Adult; D005260:Female; D006801:Humans; D008403:Mass Screening; D008875:Middle Aged; D009367:Neoplasm Staging; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000472:pathogenicity*; D030361:Papillomavirus Infections / Q000150:complications / Q000175:diagnosis*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D014412:Tumor Virus Infections / Q000150:complications / Q000175:diagnosis*; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000821:virology*; D014626:Vaginal Smears; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000821:virology